Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H12N2.ClH |
Molecular Weight | 196.677 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C(C1=NCCN1)C2=CC=CC=C2
InChI
InChIKey=RHTNTTODYGNRSP-UHFFFAOYSA-N
InChI=1S/C10H12N2.ClH/c1-2-4-9(5-3-1)8-10-11-6-7-12-10;/h1-5H,6-8H2,(H,11,12);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C10H12N2 |
Molecular Weight | 160.2157 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Tolazoline, also known as priscoline, was used in treatment of persistent pulmonary hypertension of the newborn. But that prescription was discontinued. Priscoline given intravenously produces vasodilatation, primarily due to a direct effect on vascular smooth muscle, and cardiac stimulation; the blood pressure response depends on the relative contributions of the two effects. Priscoline usually reduces pulmonary arterial pressure and vascular resistance. The mechanisms of its therapeutic effects are not clear, but is known, that tolazoline is a non-selective competitive α-adrenergic receptor antagonist and it possesses histamine agonist activity.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11938943 |
|||
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8487790 |
|||
Target ID: CHEMBL1941 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8487790 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PRISCOLINE Approved UseUnknown Launch Date-6.8774402E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3576663 |
3.2 mg single, intravenous dose: 3.2 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TOLAZOLINE blood | Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3576663 |
3.2 mg single, intravenous dose: 3.2 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TOLAZOLINE blood | Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: |
unhealthy, 36 weeks n = 47 Health Status: unhealthy Age Group: 36 weeks Population Size: 47 Sources: |
Other AEs: Erythema, Thrombocytopenia... Other AEs: Erythema (60%) Sources: Thrombocytopenia (45%) Hyponatremia (40%) Gastric acid increased (36%) Seizures (30%) Hematuria (23%) Hypotension (19%) Oliguria (11%) Abdominal distension (9%) Activity motor exaggerated (6%) Tracheal bleeding (6%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Oliguria | 11% | 2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: |
unhealthy, 36 weeks n = 47 Health Status: unhealthy Age Group: 36 weeks Population Size: 47 Sources: |
Hypotension | 19% | 2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: |
unhealthy, 36 weeks n = 47 Health Status: unhealthy Age Group: 36 weeks Population Size: 47 Sources: |
Hematuria | 23% | 2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: |
unhealthy, 36 weeks n = 47 Health Status: unhealthy Age Group: 36 weeks Population Size: 47 Sources: |
Seizures | 30% | 2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: |
unhealthy, 36 weeks n = 47 Health Status: unhealthy Age Group: 36 weeks Population Size: 47 Sources: |
Gastric acid increased | 36% | 2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: |
unhealthy, 36 weeks n = 47 Health Status: unhealthy Age Group: 36 weeks Population Size: 47 Sources: |
Hyponatremia | 40% | 2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: |
unhealthy, 36 weeks n = 47 Health Status: unhealthy Age Group: 36 weeks Population Size: 47 Sources: |
Thrombocytopenia | 45% | 2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: |
unhealthy, 36 weeks n = 47 Health Status: unhealthy Age Group: 36 weeks Population Size: 47 Sources: |
Activity motor exaggerated | 6% | 2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: |
unhealthy, 36 weeks n = 47 Health Status: unhealthy Age Group: 36 weeks Population Size: 47 Sources: |
Tracheal bleeding | 6% | 2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: |
unhealthy, 36 weeks n = 47 Health Status: unhealthy Age Group: 36 weeks Population Size: 47 Sources: |
Erythema | 60% | 2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: |
unhealthy, 36 weeks n = 47 Health Status: unhealthy Age Group: 36 weeks Population Size: 47 Sources: |
Abdominal distension | 9% | 2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: |
unhealthy, 36 weeks n = 47 Health Status: unhealthy Age Group: 36 weeks Population Size: 47 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
DDT-induced myoclonus: serotonin and alpha noradrenergic interaction. | 1979 Feb |
|
Hypochloremic metabolic alkalosis following tolazoline-induced gastric hypersecretion. | 1980 Feb |
|
[Tolazoline and dopamine in the treatment of the persistent fetal circulation syndrome]. | 1983 Oct |
|
[Renal disorders in the newborn infant]. | 1984 Jan-Feb |
|
Bolus and continuous infusion of tolazoline in neonates with hypoxemia. | 1986 |
|
Blood flow distribution and brain metabolism during tolazoline-induced hypotension in newborn dogs. | 1990 Aug |
|
Spasms of the hepatic artery following percutaneous transluminal angioplasty and tolazoline administration in a liver transplant patient. | 1996 May-Jun |
|
Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. | 1998 Apr 1 |
|
Persistent pulmonary hypertension of the newborn: experience in a single institution. | 2001 Mar-Apr |
|
Inhaled nitric oxide applications in paediatric practice. | 2002 Jan |
|
Use of azaperone and zuclopenthixol acetate to facilitate translocation of white-tailed deer (Odocoileus virginianus). | 2002 Jun |
|
[Aggression to the immature kidney]. | 2002 Mar-Apr |
|
Re: Nonlocalized lower gastrointestinal bleeding: provocative bleeding studies with intraarterial tPA, heparin, and tolazoline. | 2002 May |
|
Efficacy and safety of tolazoline for treatment of severe hypoxemia in extremely preterm infants. | 2002 May |
|
Anesthesia of polar bears using xylazine-zolazepam-tiletamine or zolazepam-tiletamine. | 2003 Jul |
|
Octopaminergic modulation of synaptic transmission between an identified sensory afferent and flight motoneuron in the locust. | 2003 Jul 14 |
|
Comparison of the vasodilating effect of nitroglycerin, verapamil, and tolazoline in hand angiography. | 2003 Jun |
|
A comparison of two intramuscular doses of xylazine-ketamine combination and tolazoline reversal in llamas. | 2004 Apr |
|
The effects of imidazoline agents on the aggregation of human platelets. | 2004 Feb |
|
Effectiveness of antagonists for tiletamine-zolazepam/xylazine immobilization in female white-tailed deer. | 2004 Jul |
|
Clinically diagnosed nonocclusive mesenteric ischemia after cardiopulmonary bypass: retrospective study. | 2004 Mar |
|
Characterisation of some pharmacological effects of the venom from Vipera lebetina. | 2004 Mar 15 |
|
2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands. | 2004 Sep 20 |
|
Prevention and management of meconium aspiration syndrome--assessment of evidence based practice. | 2005 May |
|
Clinical assessment of epidural analgesia induced by xylazine-lidocaine combination accompanied by xylazine sedation in calves. | 2005 Oct 1 |
|
Antagonism of detomidine sedation in the horse using intravenous tolazoline or atipamezole. | 2006 May |
|
A comparison of two combinations of xylazine-ketamine administered intramuscularly to alpacas and of reversal with tolazoline. | 2008 May |
|
Effect of vasoactive agents on the dermatopharmacokinetics and systemic disposition of model compounds, salicylate and FITC-dextran 4 kDa, following intracutaneous injection of the compounds. | 2008 May 22 |
|
A novel high-throughput screening assay for putative antidiabetic agents through PPARalpha interactions. | 2008 Oct |
|
Evaluation of intramuscular butorphanol, azaperone, and medetomidine and nasal oxygen insufflation for the chemical immobilization of white-tailed deer, Odocoileus virginianus. | 2008 Sep |
|
A novel approach for percutaneous treatment of massive nonocclusive mesenteric ischemia: tolazoline and glycerol trinitrate as effective local vasodilators. | 2009 Feb 1 |
|
The clinical outcomes of transcatheter microcoil embolization in patients with active lower gastrointestinal bleeding in the small bowel. | 2009 Jul-Aug |
|
Physiologic effects of nasal oxygen or medical air administered prior to and during carfentanil-xylazine anesthesia in North American elk (Cervus canadensis manitobensis). | 2009 Mar |
|
Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project. | 2010 |
|
Pharmacological characterization of a Bombyx mori alpha-adrenergic-like octopamine receptor stably expressed in a mammalian cell line. | 2010 Feb |
|
Cardiovascular effects of sub-daily levels of ambient fine particles: a systematic review. | 2010 Jun 15 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/priscoline.html
An initial dose of 1 to 2 mg/kg, via scalp vein, followed by an infusion of 1 to 2 mg/kg per hour have usually resulted in significant increases in arterial oxygen. There is very little experience with infusions lasting beyond 36 to 48 hours. Response, if it occurs, can be expected within 30 minutes after the initial dose.
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:03:33 UTC 2023
by
admin
on
Fri Dec 15 15:03:33 UTC 2023
|
Record UNII |
E669Z6S1JG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 522.2474
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
||
|
NCI_THESAURUS |
C29713
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID9021718
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY | |||
|
DBSALT000948
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY | |||
|
200-447-3
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY | |||
|
C66609
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY | |||
|
235450
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY | RxNorm | ||
|
E669Z6S1JG
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY | |||
|
CHEMBL770
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY | |||
|
6048
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY | |||
|
1669004
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY | |||
|
757353
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY | |||
|
m10936
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY | Merck Index | ||
|
E669Z6S1JG
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY | |||
|
100000084634
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY | |||
|
59-97-2
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY | |||
|
SUB04906MIG
Created by
admin on Fri Dec 15 15:03:33 UTC 2023 , Edited by admin on Fri Dec 15 15:03:33 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |